Literature DB >> 33188775

Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease.

Hendrik Wesseling1, Waltraud Mair1, Mukesh Kumar1, Christoph N Schlaffner1, Shaojun Tang2, Pieter Beerepoot1, Benoit Fatou3, Amanda J Guise1, Long Cheng1, Shuko Takeda4, Jan Muntel3, Melissa S Rotunno3, Simon Dujardin5, Peter Davies6, Kenneth S Kosik7, Bruce L Miller8, Sabina Berretta9, John C Hedreen9, Lea T Grinberg10, William W Seeley10, Bradley T Hyman5, Hanno Steen3, Judith A Steen11.   

Abstract

To elucidate the role of Tau isoforms and post-translational modification (PTM) stoichiometry in Alzheimer's disease (AD), we generated a high-resolution quantitative proteomics map of 95 PTMs on multiple isoforms of Tau isolated from postmortem human tissue from 49 AD and 42 control subjects. Although Tau PTM maps reveal heterogeneity across subjects, a subset of PTMs display high occupancy and frequency for AD, suggesting importance in disease. Unsupervised analyses indicate that PTMs occur in an ordered manner, leading to Tau aggregation. The processive addition and minimal set of PTMs associated with seeding activity was further defined by analysis of size-fractionated Tau. To summarize, features in the Tau protein critical for disease intervention at different stages of disease are identified, including enrichment of 0N and 4R isoforms, underrepresentation of the C terminus, an increase in negative charge in the proline-rich region (PRR), and a decrease in positive charge in the microtubule binding domain (MBD).
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FLEXITau; absolute quantification; disease progression; multiple reaction monitoring (MRM); post-translational modifications; prion-like molecules; protein aggregation; proteomics; proteopathy; quantitative mass spectrometry

Mesh:

Substances:

Year:  2020        PMID: 33188775     DOI: 10.1016/j.cell.2020.10.029

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  91 in total

1.  Isotopic N,N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease.

Authors:  Yuan Liu; Hua Zhang; Xiaofang Zhong; Zihui Li; Henrik Zetterberg; Lingjun Li
Journal:  J Proteomics       Date:  2022-02-03       Impact factor: 4.044

Review 2.  The different autophagy degradation pathways and neurodegeneration.

Authors:  Angeleen Fleming; Mathieu Bourdenx; Motoki Fujimaki; Cansu Karabiyik; Gregory J Krause; Ana Lopez; Adrián Martín-Segura; Claudia Puri; Aurora Scrivo; John Skidmore; Sung Min Son; Eleanna Stamatakou; Lidia Wrobel; Ye Zhu; Ana Maria Cuervo; David C Rubinsztein
Journal:  Neuron       Date:  2022-02-07       Impact factor: 17.173

3.  Putting Humpty Dumpty Back Together Again: What Does Protein Quantification Mean in Bottom-Up Proteomics?

Authors:  Deanna L Plubell; Lukas Käll; Bobbie-Jo Webb-Robertson; Lisa M Bramer; Ashley Ives; Neil L Kelleher; Lloyd M Smith; Thomas J Montine; Christine C Wu; Michael J MacCoss
Journal:  J Proteome Res       Date:  2022-02-27       Impact factor: 4.466

4.  Heterotypic Amyloid β interactions facilitate amyloid assembly and modify amyloid structure.

Authors:  Katerina Konstantoulea; Patricia Guerreiro; Meine Ramakers; Nikolaos Louros; Liam D Aubrey; Bert Houben; Emiel Michiels; Matthias De Vleeschouwer; Yulia Lampi; Luís F Ribeiro; Joris de Wit; Wei-Feng Xue; Joost Schymkowitz; Frederic Rousseau
Journal:  EMBO J       Date:  2021-11-29       Impact factor: 11.598

5.  Reducing acetylated tau is neuroprotective in brain injury.

Authors:  Min-Kyoo Shin; Edwin Vázquez-Rosa; Yeojung Koh; Matasha Dhar; Kalyani Chaubey; Coral J Cintrón-Pérez; Sarah Barker; Emiko Miller; Kathryn Franke; Maria F Noterman; Divya Seth; Rachael S Allen; Cara T Motz; Sriganesh Ramachandra Rao; Lara A Skelton; Machelle T Pardue; Steven J Fliesler; Chao Wang; Tara E Tracy; Li Gan; Daniel J Liebl; Jude P J Savarraj; Glenda L Torres; Hilda Ahnstedt; Louise D McCullough; Ryan S Kitagawa; H Alex Choi; Pengyue Zhang; Yuan Hou; Chien-Wei Chiang; Lang Li; Francisco Ortiz; Jessica A Kilgore; Noelle S Williams; Victoria C Whitehair; Tamar Gefen; Margaret E Flanagan; Jonathan S Stamler; Mukesh K Jain; Allison Kraus; Feixiong Cheng; James D Reynolds; Andrew A Pieper
Journal:  Cell       Date:  2021-04-13       Impact factor: 41.582

6.  Tau seeds are subject to aberrant modifications resulting in distinct signatures.

Authors:  Jui-Heng Tseng; Aditi Ajit; Zarin Tabassum; Niyati Patel; Xu Tian; Youjun Chen; Alex W Prevatte; Karen Ling; Frank Rigo; Rick B Meeker; Laura E Herring; Todd J Cohen
Journal:  Cell Rep       Date:  2021-04-27       Impact factor: 9.423

7.  Dephosphorylation Passivates the Seeding Activity of Oligomeric Tau Derived From Alzheimer's Brain.

Authors:  Ruozhen Wu; Longfei Li; Ruirui Shi; Yan Zhou; Nana Jin; Jianlan Gu; Yunn Chyn Tung; Fei Liu; Dandan Chu
Journal:  Front Mol Neurosci       Date:  2021-05-13       Impact factor: 5.639

8.  TBK1 interacts with tau and enhances neurodegeneration in tauopathy.

Authors:  Measho H Abreha; Shamsideen Ojelade; Eric B Dammer; Zachary T McEachin; Duc M Duong; Marla Gearing; Gary J Bassell; James J Lah; Allan I Levey; Joshua M Shulman; Nicholas T Seyfried
Journal:  J Biol Chem       Date:  2021-05-07       Impact factor: 5.157

9.  Dysregulated coordination of MAPT exon 2 and exon 10 splicing underlies different tau pathologies in PSP and AD.

Authors:  Kathryn R Bowles; Derian A Pugh; Laura-Maria Oja; Benjamin M Jadow; Kurt Farrell; Kristen Whitney; Abhijeet Sharma; Jonathan D Cherry; Towfique Raj; Ana C Pereira; John F Crary; Alison M Goate
Journal:  Acta Neuropathol       Date:  2021-12-07       Impact factor: 17.088

Review 10.  "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.

Authors:  Yuxing Xia; Stefan Prokop; Benoit I Giasson
Journal:  Mol Neurodegener       Date:  2021-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.